|
CBR4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.0087000000002E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.423440E-03 |
| Normal-vs-Stage2 |
3.882400E-02 |
| Normal-vs-Stage3 |
5.9503999999988E-05 |
| Normal-vs-Stage4 |
2.54609999750244E-09 |
| Stage1-vs-Stage2 |
6.220000E-01 |
| Stage1-vs-Stage3 |
1.399390E-01 |
| Stage1-vs-Stage4 |
7.91220000000425E-05 |
| Stage2-vs-Stage3 |
1.726180E-01 |
| Stage2-vs-Stage4 |
3.083700E-03 |
| Stage3-vs-Stage4 |
6.481800E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.81721999999995E-05 |
| Normal-vs-AfricanAmerican |
2.444000E-02 |
| Normal-vs-Asian |
1.7218899999949E-05 |
| Caucasian-vs-AfricanAmerican |
6.032000E-01 |
| Caucasian-vs-Asian |
4.940200E-01 |
| AfricanAmerican-vs-Asian |
4.447400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.500200E-03 |
| Normal-vs-Female |
3.71980000000161E-05 |
| Male-vs-Female |
9.794300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.159040E-03 |
| Normal-vs-Age(41-60Yrs) |
3.50249999999663E-05 |
| Normal-vs-Age(61-80Yrs) |
6.425300E-04 |
| Normal-vs-Age(81-100Yrs) |
1.720460E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.036600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.481000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.635200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.229200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.533400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.262800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.07780000000191E-06 |
| Classical-VS-Follicular |
7.048600E-04 |
| Classical-VS-Other |
4.103600E-01 |
| Classical-VS-Normal |
3.92240000002264E-06 |
| Tall-VS-Follicular |
4.75460004700778E-09 |
| Tall-VS-Other |
1.172170E-01 |
| Tall-VS-Normal |
1.18050014208393E-11 |
| Follicular-VS-Other |
9.285800E-01 |
| Follicular-VS-Normal |
6.003200E-01 |
| Other-VS-Normal |
8.066600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.576200E-03 |
| Normal-vs-N1 |
3.82310000002217E-06 |
| N0-vs-N1 |
2.222000E-02 |
|
|
